Coronary artery disease (CAD) is one of the leading causes of heart attacks and strokes around the world. It develops when fatty deposits build up inside the arteries that supply blood to the heart, making them narrower and reducing blood flow.
People living with CAD often need lifelong treatment to lower the risk of serious complications, including heart attacks, strokes, and early death.
For decades, aspirin has been the standard medicine used to help prevent blood clots in people with coronary artery disease.
Aspirin works by making blood platelets less likely to stick together, reducing the chance of dangerous clots forming inside narrowed arteries. However, researchers have continued to investigate whether other blood-thinning medicines might provide even better protection.
A new study published in The Lancet suggests that clopidogrel may be a better option for many people with coronary artery disease.
Researchers analysed information from nearly 29,000 participants enrolled in seven clinical trials. By combining the results of several high-quality studies, the researchers were able to gain a clearer picture of how the two medicines compare over the long term.
The analysis found that people taking clopidogrel had a 14% lower risk of experiencing a major cardiovascular event, such as a heart attack or stroke, compared with those taking aspirin. These findings challenge the long-standing belief that aspirin should always be the first choice for long-term treatment after coronary artery disease has been diagnosed.
One of the biggest concerns with medicines that reduce blood clotting is the risk of bleeding. Because these drugs make it harder for blood to clot, they can sometimes increase the chance of serious bleeding. Reassuringly, the researchers found that people taking clopidogrel did not have a higher risk of major bleeding than those taking aspirin. This suggests the medicine may provide stronger protection without increasing this important safety risk.
The study included a wide range of patients with coronary artery disease. Some participants had previously undergone procedures to place stents in narrowed arteries, while others had experienced serious heart problems such as heart attacks. This broad range of patients makes the findings more relevant to everyday medical practice.
The researchers also examined whether genetic differences or other clinical factors influenced the results. Some people are known to respond less effectively to clopidogrel because of inherited differences in how their bodies process the medicine. Even in these groups, clopidogrel still appeared to provide better overall protection than aspirin.
Because both aspirin and clopidogrel are widely available and already used in hospitals and clinics around the world, these findings could have an important impact on future treatment guidelines. If additional research confirms these results, doctors may increasingly choose clopidogrel instead of aspirin for long-term prevention in people with established coronary artery disease.
The researchers emphasise that more studies are still needed to examine the long-term cost-effectiveness of clopidogrel and confirm its benefits in even larger and more diverse patient populations. These studies will help determine whether clopidogrel should eventually replace aspirin as the preferred long-term treatment for most people with coronary artery disease.
The study was published in The Lancet. Although patients should never change their medication without medical advice, the findings provide encouraging evidence that a commonly used medicine may offer better protection against heart attacks and strokes while maintaining a similar safety profile.
This research could eventually improve the care of millions of people living with heart disease worldwide.
If you care about heart health, please read studies about how eating eggs can help reduce heart disease risk, and herbal supplements could harm your heart rhythm.
For more health information, please see recent studies about how drinking milk affects risks of heart disease and cancer, and results showing strawberries could help prevent Alzheimer’s disease.
Copyright © 2026 Knowridge Science Report. All rights reserved.
